Western Blot (WB)
(Western Blot of immunogen using MBS602061.)
Mouse anti-Human v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived Monoclonal Antibody | anti-MYCN antibody
v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived (avian) (MYCN, MODED, ODED)
Gene Names
MYCN; NMYC; ODED; MODED; N-myc; bHLHe37; MYCN
Reactivity
Human
Applications
Western Blot
Purity
Affinity PurifiedPurified by Protein G affinity chromatography.
Synonyms
v-Myc Myelocytomatosis Viral Related Oncogene; Neuroblastoma Derived; Monoclonal Antibody; Neuroblastoma Derived (avian) (MYCN; MODED; ODED); Anti -v-Myc Myelocytomatosis Viral Related Oncogene; anti-MYCN antibody
Host
Mouse
Reactivity
Human
Clonality
Monoclonal
Isotype
IgG1
Clone Number
8C227
Specificity
Recognizes human v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived (avian).
Purity/Purification
Affinity Purified
Purified by Protein G affinity chromatography.
Purified by Protein G affinity chromatography.
Form/Format
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.05% sodium azide.
Applicable Applications for anti-MYCN antibody
Western Blot (WB)
Application Notes
Suitable for use in Western Blot.
Immunogen
Recombinant corresponding to a partial sequence from human v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived (avian).
Preparation and Storage
May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Western Blot (WB)
(Western Blot of immunogen using MBS602061.)
Western Blot (WB)
(Western Blot of immunogen using MBS602061.)
Related Product Information for anti-MYCN antibody
This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.
Product Categories/Family for anti-MYCN antibody
NCBI and Uniprot Product Information
NCBI GI #
NCBI GeneID
Molecular Weight
49,561 Da
NCBI Official Full Name
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
NCBI Official Synonym Full Names
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
NCBI Official Symbol
MYCN
NCBI Official Synonym Symbols
NMYC; ODED; MODED; N-myc; bHLHe37; MYCN
NCBI Protein Information
N-myc proto-oncogene protein; pp65/67; oncogene NMYC; neuroblastoma MYC oncogene; class E basic helix-loop-helix protein 37; neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene; v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
UniProt Protein Name
N-myc proto-oncogene protein
Protein Family
UniProt Gene Name
MYCN
UniProt Synonym Gene Names
BHLHE37; NMYC
UniProt Entry Name
MYCN_HUMAN
NCBI Description
This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas. [provided by RefSeq]
Uniprot Description
N-Myc: a proto-oncogenic transcription factor. Plays a role in cell proliferation, apoptosis and in the development of human tumors.
Protein type: Transcription factor; Oncoprotein; DNA-binding
Chromosomal Location of Human Ortholog: 2p24.3
Cellular Component: chromatin; nucleus
Molecular Function: protein dimerization activity; protein binding; DNA binding; transcription factor activity
Biological Process: regulation of transcription from RNA polymerase II promoter; branching morphogenesis of a tube; positive regulation of mesenchymal cell proliferation; negative regulation of astrocyte differentiation; positive regulation of transcription from RNA polymerase II promoter; embryonic digit morphogenesis; embryonic skeletal morphogenesis; cartilage condensation; lung development
Disease: Feingold Syndrome 1; Tracheoesophageal Fistula With Or Without Esophageal Atresia
Research Articles on MYCN
1. Regulation of GCL(cat) by MYCN accounts for the survival of neuroblastoma cells against oxidative damage; GCL should be considered a potential therapeutic target for the treatment of MYCN-amplified neuroblastoma.
2. Targeted expression of MYCN thus contributes to initiation, progression, and maintenance of MB, suggesting a central role for MYCN in pathogenesis
3. VEGFR-1 and sVEGFR-2, and upregulation of angiogenic activators VEGF-A and VEGF-D in MYCN-amplified stage IV neuroblastoma supports the crucial effect of this oncogene on neuroblastoma progression
4. Increasing extracellular matrix stiffness also reduces expression of N-Myc, a transcription factor involved in multiple aspects of oncogenic proliferation.
5. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
6. SKP2 activation through the transcriptional start site in MYCN-amplified cells is associated with the low abundance of pRB-E2F1 complexes bound to the SKP2 promoter in neuroblastoma.
7. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.
8. analysis of MiRNA dysregulation by MYCN amplification and chromosomal imbalances in neuroblastoma
9. miR-9 miRNA downregulates E-cadherin. Expression of miR-9 is activated by MYC and MYCN, which bind to the mir-9-3 locus. Elevated expression of miR-9 may contribute to epithelial-mesenchymal transition and metastasis in some and possibly many tumours.
10. MYCN transcriptionally upregulates p53 in neuroblastoma and uses p53 to mediate a key mechanism of apoptosis.
2. Targeted expression of MYCN thus contributes to initiation, progression, and maintenance of MB, suggesting a central role for MYCN in pathogenesis
3. VEGFR-1 and sVEGFR-2, and upregulation of angiogenic activators VEGF-A and VEGF-D in MYCN-amplified stage IV neuroblastoma supports the crucial effect of this oncogene on neuroblastoma progression
4. Increasing extracellular matrix stiffness also reduces expression of N-Myc, a transcription factor involved in multiple aspects of oncogenic proliferation.
5. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
6. SKP2 activation through the transcriptional start site in MYCN-amplified cells is associated with the low abundance of pRB-E2F1 complexes bound to the SKP2 promoter in neuroblastoma.
7. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.
8. analysis of MiRNA dysregulation by MYCN amplification and chromosomal imbalances in neuroblastoma
9. miR-9 miRNA downregulates E-cadherin. Expression of miR-9 is activated by MYC and MYCN, which bind to the mir-9-3 locus. Elevated expression of miR-9 may contribute to epithelial-mesenchymal transition and metastasis in some and possibly many tumours.
10. MYCN transcriptionally upregulates p53 in neuroblastoma and uses p53 to mediate a key mechanism of apoptosis.
Similar Products
Product Notes
The MYCN mycn (Catalog #AAA602061) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived (avian) (MYCN, MODED, ODED) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB). Suitable for use in Western Blot. Researchers should empirically determine the suitability of the MYCN mycn for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "v-Myc Myelocytomatosis Viral Related Oncogene, Neuroblastoma Derived, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
